MTA3

Across TCGA pan-cancer cohorts, MTA3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MTA3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MTA3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MTA3 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where MTA3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTA3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.768	<.001	9	view →
LUAD	Female	II,III,IV	+0.519	<.001	9	view →
CCRCC	Male	II,III,IV	−0.172	<.001	6	view →
HNSC	Male	III,IV	+0.164	.016	2	view →
PDAC	All	IV	+0.233	.037	1	view →
COAD	Female	All	+0.128	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MTA3–LSCC

Open the LSCC breakdown →